董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Barry Fishman | 男 | Lead Independent Director | 68 | 未披露 | 未持股 | 2023-06-29 |
| Dieter Weinand | 男 | Director | 64 | 未披露 | 未持股 | 2023-06-29 |
| Ellen Lubman | 女 | Director | 49 | 未披露 | 未持股 | 2023-06-29 |
| Fred Grossman | 男 | Director | 62 | 未披露 | 未持股 | 2023-06-29 |
| Joseph del Moral | 男 | Chairman of the Board | NLL | 未披露 | 未持股 | 2023-06-29 |
| Hannan Fleiman | 男 | Director | -- | 未披露 | 未持股 | 2023-06-29 |
| Helen Boudreau | 女 | Director | 59 | 未披露 | 未持股 | 2023-06-29 |
| Dieter Weinand | 男 | Director | -- | 未披露 | 未持股 | 2023-06-29 |
| Fred Grossman | 男 | Director | -- | 未披露 | 未持股 | 2023-06-29 |
| Greg Mayes | 男 | Director, President and CEO | -- | 未披露 | 未持股 | 2023-06-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edward Smith | 男 | Chief Financial Officer | 54 | 未披露 | 未持股 | 2023-06-29 |
| Greg Mayes | 男 | Director, President and CEO | -- | 未披露 | 未持股 | 2023-06-29 |
| Robert Alexander | 男 | Chief Medical Officer | -- | 未披露 | 未持股 | 2023-06-29 |
| Nathan Bryson | 男 | Chief Science Officer | -- | 未披露 | 未持股 | 2023-06-29 |
| Curtis Weber | 男 | General Counsel | -- | 未披露 | 未持股 | 2023-06-29 |
董事简历
中英对照 | 中文 | 英文- Barry Fishman
-
Barry Fishman，自2023年9月起担任Medicus Pharma Ltd.董事会成员。Fishman先生作为创业企业领导者拥有近25年的经验，最近担任VIVO Cannabis Inc.的首席执行官（2017年至2020年）。在加入VIVO之前，Fishman先生曾担任国际专业制药公司Merus实验室的首席执行官（2014年至2017年），通过其2017年被Norgine M.V.收购。他此前还曾担任梯瓦加拿大公司（Teva Canada）的首席执行官（2003年至2014年），该公司是这家全球最大的仿制药制造商的主要附属公司，并在加拿大礼来开始了他的制药生涯，曾担任市场营销副总裁（1983年至2000年）。Fishman先生最近还在多个备受瞩目的董事会担任独立董事，包括Aurora Cannabis公司和Canopy Growth Corporation。Fishman先生毕业于麦吉尔大学，主修金融，随后在南加州的德勤工作期间成为一名注册会计师。
Barry Fishman has served as a member of the Board since September 2023.Mr. Fishman has almost 25 years of experience as an entrepreneurial biness leader, he has held executive leadership roles in branded and generic pharmaceutical companies including Eli Lilly, Taro, Teva, and Mer Labs a Canadian based publicly traded international specialty pharmaceutical company foced on branded legacy and growth brands. Mr. Fishman has significant experience as a public company director and is a past Chair of the Canadian Generic Pharmaceutical Association (CGPA). Mr. Fishman has also recently served as an independent director on a number of high profile boards, including Aurora Cannabis Inc. and Canopy Growth Corporation. Mr. Fishman graduated from McGill University with a concentration in finance and nt on to become a CPA while working for Deloitte in Southern California. - Barry Fishman，自2023年9月起担任Medicus Pharma Ltd.董事会成员。Fishman先生作为创业企业领导者拥有近25年的经验，最近担任VIVO Cannabis Inc.的首席执行官（2017年至2020年）。在加入VIVO之前，Fishman先生曾担任国际专业制药公司Merus实验室的首席执行官（2014年至2017年），通过其2017年被Norgine M.V.收购。他此前还曾担任梯瓦加拿大公司（Teva Canada）的首席执行官（2003年至2014年），该公司是这家全球最大的仿制药制造商的主要附属公司，并在加拿大礼来开始了他的制药生涯，曾担任市场营销副总裁（1983年至2000年）。Fishman先生最近还在多个备受瞩目的董事会担任独立董事，包括Aurora Cannabis公司和Canopy Growth Corporation。Fishman先生毕业于麦吉尔大学，主修金融，随后在南加州的德勤工作期间成为一名注册会计师。
- Barry Fishman has served as a member of the Board since September 2023.Mr. Fishman has almost 25 years of experience as an entrepreneurial biness leader, he has held executive leadership roles in branded and generic pharmaceutical companies including Eli Lilly, Taro, Teva, and Mer Labs a Canadian based publicly traded international specialty pharmaceutical company foced on branded legacy and growth brands. Mr. Fishman has significant experience as a public company director and is a past Chair of the Canadian Generic Pharmaceutical Association (CGPA). Mr. Fishman has also recently served as an independent director on a number of high profile boards, including Aurora Cannabis Inc. and Canopy Growth Corporation. Mr. Fishman graduated from McGill University with a concentration in finance and nt on to become a CPA while working for Deloitte in Southern California.
- Dieter Weinand
-
Dieter Weinand自2018年6月起担任董事会成员，自2020年4月起担任主席。从2018年11月至2020年3月，魏南德先生担任赛诺菲公司初级保健执行Vice President，他曾于2014年至2018年担任拜耳公司制药部门总裁。2013年至2014年，Weinand先生担任大冢制药有限公司全球商业化总裁，2010年至2013年，Weinand先生担任辉瑞公司初级保健和亚太地区总裁2001年至2010年，Weinand先生担任百时美施贵宝公司高级副总裁，和Vice President总裁。在加入百时美施贵宝公司之前，魏南德从2000年到2001年担任F.H.福丁公司（F.H.Faulding，Inc.）的高级副总裁，担任华纳-兰伯特公司（Warner-Lambert Company）的董事总经理、Vice President主管和高级主管，该公司于2000年在1994年至2000年期间被辉瑞公司收购，1994年期间在Pharmos Corporation担任Vice President，1990年至1994年期间在Lederle International担任董事、地区业务运营协调员和国际产品经理。Weinand先生此前曾于2013年至2014年担任拜耳股份公司的董事会成员，并于2014年至2018年担任HealthPrize Technologies LLC的董事会成员。Weinand先生于1987年在长岛大学（Long Island University）获得药理学与毒理学硕士学位，并于1982年在康科迪亚学院（Concordia College）获得文学学士学位。
Dieter Weinand,was previously the Chairperson of the Board from April 2020 to April 2024. From November 2018 to March 2020, Mr. Weinand served as Executive Vice President, Primary Care of Sanofi S.A. He previously served as President and CEO, Pharmaceutical Division at Bayer AG from 2014 to 2018. From 2013 to 2014, Mr. Weinand was President, Global Commercialization at Otsuka Pharmaceutical Co., Ltd. and from 2010 to 2013 Mr. Weinand was President, Primary Care and Asia-Pacific Region at Pfizer Inc. From 2001 to 2010, Mr. Weinand served as President, Senior Vice President, and Vice President of Bristol-Myers Squibb Company. Prior to joining Bristol-Myers Squibb Company, Mr. Weinand was Senior Vice President at F.H. Faulding, Inc. from 2000 to 2001, Managing Director, Director, Vice President, and Senior Director at Warner-Lambert Company, which was acquired by Pfizer Inc. in 2000, during the period from 1994 to 2000, Vice President at Pharmos Corporation during 1994, and Director, Area Business Operations Coordinator, and International Product Manager at Lederle International during the period from 1990 to 1994. Mr. Weinand currently serves on the board of directors of Reunion Neuroscience, Inc., a clinical stage pharmaceutical company and Coya Therapeutics, a NASDAQ-listed clinical-stage biotechnology company. Previously, Mr. Weinand was a member the board of directors of Bayer AG, from 2013 to 2014, and HealthPrize Technologies LLC, from 2014 to 2018. Mr. Weinand was a director and member of the compensation committee and chair of the audit committee of Filed Trip Health Ltd. from October 2019 to July 2022. Mr. Weinand received a M.S. in Pharmacology and Toxicology from Long Island University and a B.A. in Biology from Concordia College. - Dieter Weinand自2018年6月起担任董事会成员，自2020年4月起担任主席。从2018年11月至2020年3月，魏南德先生担任赛诺菲公司初级保健执行Vice President，他曾于2014年至2018年担任拜耳公司制药部门总裁。2013年至2014年，Weinand先生担任大冢制药有限公司全球商业化总裁，2010年至2013年，Weinand先生担任辉瑞公司初级保健和亚太地区总裁2001年至2010年，Weinand先生担任百时美施贵宝公司高级副总裁，和Vice President总裁。在加入百时美施贵宝公司之前，魏南德从2000年到2001年担任F.H.福丁公司（F.H.Faulding，Inc.）的高级副总裁，担任华纳-兰伯特公司（Warner-Lambert Company）的董事总经理、Vice President主管和高级主管，该公司于2000年在1994年至2000年期间被辉瑞公司收购，1994年期间在Pharmos Corporation担任Vice President，1990年至1994年期间在Lederle International担任董事、地区业务运营协调员和国际产品经理。Weinand先生此前曾于2013年至2014年担任拜耳股份公司的董事会成员，并于2014年至2018年担任HealthPrize Technologies LLC的董事会成员。Weinand先生于1987年在长岛大学（Long Island University）获得药理学与毒理学硕士学位，并于1982年在康科迪亚学院（Concordia College）获得文学学士学位。
- Dieter Weinand,was previously the Chairperson of the Board from April 2020 to April 2024. From November 2018 to March 2020, Mr. Weinand served as Executive Vice President, Primary Care of Sanofi S.A. He previously served as President and CEO, Pharmaceutical Division at Bayer AG from 2014 to 2018. From 2013 to 2014, Mr. Weinand was President, Global Commercialization at Otsuka Pharmaceutical Co., Ltd. and from 2010 to 2013 Mr. Weinand was President, Primary Care and Asia-Pacific Region at Pfizer Inc. From 2001 to 2010, Mr. Weinand served as President, Senior Vice President, and Vice President of Bristol-Myers Squibb Company. Prior to joining Bristol-Myers Squibb Company, Mr. Weinand was Senior Vice President at F.H. Faulding, Inc. from 2000 to 2001, Managing Director, Director, Vice President, and Senior Director at Warner-Lambert Company, which was acquired by Pfizer Inc. in 2000, during the period from 1994 to 2000, Vice President at Pharmos Corporation during 1994, and Director, Area Business Operations Coordinator, and International Product Manager at Lederle International during the period from 1990 to 1994. Mr. Weinand currently serves on the board of directors of Reunion Neuroscience, Inc., a clinical stage pharmaceutical company and Coya Therapeutics, a NASDAQ-listed clinical-stage biotechnology company. Previously, Mr. Weinand was a member the board of directors of Bayer AG, from 2013 to 2014, and HealthPrize Technologies LLC, from 2014 to 2018. Mr. Weinand was a director and member of the compensation committee and chair of the audit committee of Filed Trip Health Ltd. from October 2019 to July 2022. Mr. Weinand received a M.S. in Pharmacology and Toxicology from Long Island University and a B.A. in Biology from Concordia College.
- Ellen Lubman
-
Ellen Lubman自2020年8月起担任我们的首席商务官。从2018年10月至2020年7月，Lubman女士担任Impel NeuroPharma，Inc.（一家专注于神经系统疾病的私人生物技术公司）的首席商务官。任职Impel公司之前，她曾担任Forest Labs公司的外部科学与创新Vice President（从2014年2月到2014年7月被Actavis plc收购），也曾担任Actavis公司的相同职务，直到2018年6月Actavis公司与Allergan plc公司合并并更名为Actavis公司。加入Allergan之前，Lubman在Kadmon Pharmaceuticals，Bristol Myers Squibb，Celtic Pharma Management，L.P.，Robertson Stephens Investment Bank和Abbott Labs担任多个执行和领导职位。她任职于GeneCentric Therapeutics公司和Intrepida Bio公司的董事会，以及TMRW.org公司的顾问委员会。Lubman女士目前还担任Weill-Cornell的Daedalus Innovation Fund的科学顾问委员会和Gilda’；s Club of NYC的董事会成员，并且是Bio的南加州执行妇女主席。Lubman女士在斯坦福大学商学院（Stanford Graduate School of Business）获得工商管理硕士学位，专注于全球管理，并在罗格斯学院（Rutgers College）获得生物学学士学位。
Ellen Lubman has served as our Chief Business Officer since August 2020. From October 2018 to July 2020 Ms. Lubman served as the Chief Business Officer at Impel NeuroPharma, Inc., a privately held biotechnology company focused on neurological diseases. Prior to Impel, she was the Vice President of External Science & Innovation at Forest Labs, from February 2014 until its acquisition by Actavis plc in July 2014 and served in the same role at Actavis through June 2018 during which time Actavis merged with and renamed itself Allergan plc. Prior to Allergan, Ms. Lubman held numerous executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank and Abbott Labs. She serves on the board of directors of GeneCentric Therapeutics and Intrepida Bio, as well as the Advisory Board of TMRW.org. Ms. Lubman also currently serves on the Scientific Advisory Board of the Daedalus Innovation Fund of Weill-Cornell and board of directors of Gilda’s Club of NYC and is the Southern California Chairwoman of Executive Women in BIO. Ms. Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College. - Ellen Lubman自2020年8月起担任我们的首席商务官。从2018年10月至2020年7月，Lubman女士担任Impel NeuroPharma，Inc.（一家专注于神经系统疾病的私人生物技术公司）的首席商务官。任职Impel公司之前，她曾担任Forest Labs公司的外部科学与创新Vice President（从2014年2月到2014年7月被Actavis plc收购），也曾担任Actavis公司的相同职务，直到2018年6月Actavis公司与Allergan plc公司合并并更名为Actavis公司。加入Allergan之前，Lubman在Kadmon Pharmaceuticals，Bristol Myers Squibb，Celtic Pharma Management，L.P.，Robertson Stephens Investment Bank和Abbott Labs担任多个执行和领导职位。她任职于GeneCentric Therapeutics公司和Intrepida Bio公司的董事会，以及TMRW.org公司的顾问委员会。Lubman女士目前还担任Weill-Cornell的Daedalus Innovation Fund的科学顾问委员会和Gilda’；s Club of NYC的董事会成员，并且是Bio的南加州执行妇女主席。Lubman女士在斯坦福大学商学院（Stanford Graduate School of Business）获得工商管理硕士学位，专注于全球管理，并在罗格斯学院（Rutgers College）获得生物学学士学位。
- Ellen Lubman has served as our Chief Business Officer since August 2020. From October 2018 to July 2020 Ms. Lubman served as the Chief Business Officer at Impel NeuroPharma, Inc., a privately held biotechnology company focused on neurological diseases. Prior to Impel, she was the Vice President of External Science & Innovation at Forest Labs, from February 2014 until its acquisition by Actavis plc in July 2014 and served in the same role at Actavis through June 2018 during which time Actavis merged with and renamed itself Allergan plc. Prior to Allergan, Ms. Lubman held numerous executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank and Abbott Labs. She serves on the board of directors of GeneCentric Therapeutics and Intrepida Bio, as well as the Advisory Board of TMRW.org. Ms. Lubman also currently serves on the Scientific Advisory Board of the Daedalus Innovation Fund of Weill-Cornell and board of directors of Gilda’s Club of NYC and is the Southern California Chairwoman of Executive Women in BIO. Ms. Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College.
- Fred Grossman
-
Fred Grossman，自2023年7月起担任总裁兼首席医疗官。他与世界各地的思想领袖有着密切的关系，并与FDA和全球卫生当局就跨治疗领域的许多药物的批准进行了直接谈判。Grossman博士曾在礼来、强生、百时美施贵宝和Sunovion担任高管职务。他曾在Glenmark Pharmaceuticals（BSE；532296）担任总裁兼首席医疗官，这家总部位于印度、年产值15亿美元的全球制药公司负责监督包括仿制药、包括505（b）（2）候选药物在内的复杂仿制药以及下一代生物制剂（包括双特异性抗体）在内的整个管道的开发。他此前还曾在Mesoblast，Inc.（NASDQ：MESO）担任首席医疗官，开发针对炎症性疾病的同种异体细胞疗法。格罗斯曼博士获得精神病学委员会认证，是美国精神病学协会的会员，曾是美国国立卫生研究院（NIH）的会员。他担任过几次学术职务，并撰写了许多科学出版物。
Fred Grossman,has been President and Chief Medical Officer since July 2023. He has close relationships with thought leaders worldwide and has negotiated directly with the FDA and Global Health Authorities for approval of many drugs across therapeutic areas. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals (BSE; 532296), at $1.5 Billion per annum global pharmaceutical company based in India, overseeing development of the entire pipeline including generics, complex generics including 505(b)(2) candidates, and next-generation biologics (including bi-specific antibodies). He also previously served as Chief Medical Officer at Mesoblast, Inc. (NASDQ: MESO), developing allogeneic cellular therapies for inflammatory diseases. Dr. Grossman is Board-Certified in Psychiatry and a Fellow of the American Psychiatric Association and was a Fellow at the National Institutes of Health (NIH). He has held several academic appointments and authored numerous scientific publications. - Fred Grossman，自2023年7月起担任总裁兼首席医疗官。他与世界各地的思想领袖有着密切的关系，并与FDA和全球卫生当局就跨治疗领域的许多药物的批准进行了直接谈判。Grossman博士曾在礼来、强生、百时美施贵宝和Sunovion担任高管职务。他曾在Glenmark Pharmaceuticals（BSE；532296）担任总裁兼首席医疗官，这家总部位于印度、年产值15亿美元的全球制药公司负责监督包括仿制药、包括505（b）（2）候选药物在内的复杂仿制药以及下一代生物制剂（包括双特异性抗体）在内的整个管道的开发。他此前还曾在Mesoblast，Inc.（NASDQ：MESO）担任首席医疗官，开发针对炎症性疾病的同种异体细胞疗法。格罗斯曼博士获得精神病学委员会认证，是美国精神病学协会的会员，曾是美国国立卫生研究院（NIH）的会员。他担任过几次学术职务，并撰写了许多科学出版物。
- Fred Grossman,has been President and Chief Medical Officer since July 2023. He has close relationships with thought leaders worldwide and has negotiated directly with the FDA and Global Health Authorities for approval of many drugs across therapeutic areas. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals (BSE; 532296), at $1.5 Billion per annum global pharmaceutical company based in India, overseeing development of the entire pipeline including generics, complex generics including 505(b)(2) candidates, and next-generation biologics (including bi-specific antibodies). He also previously served as Chief Medical Officer at Mesoblast, Inc. (NASDQ: MESO), developing allogeneic cellular therapies for inflammatory diseases. Dr. Grossman is Board-Certified in Psychiatry and a Fellow of the American Psychiatric Association and was a Fellow at the National Institutes of Health (NIH). He has held several academic appointments and authored numerous scientific publications.
- Joseph del Moral
-
Joseph del Moral是一位经验丰富的企业家，也是Reunion的创始人，曾担任首席执行官至2022年9月。2014年，他是CanvasRx Inc.和Canadian Cannabis Clinics的创始人和首席执行官，后者成长为加拿大最大的大麻诊所公司。2016年，CanvasRx被Aurora Cannabis Inc.（纽约证券交易所代码：ACB）（“Aurora”）收购，他加入了Aurora的董事会。在Aurora任职期间，del Moral先生确保CanvasRx继续发展并实现其里程碑，并协助公司发展、并购和战略。2018年离开Aurora后，德尔莫拉尔担任大麻和大麻行业领先的生物技术公司Trait Biosciences Inc.的首席执行官。在进入大麻行业之前，德尔莫拉尔与他人共同创立了Newten Home Comfort，这是一家快速发展的家庭服务公司，于2009年被Just Energy Inc.收购。2001年6月，del Moral先生被麦吉尔大学授予商业学士学位（金融和创业）。
Joseph del Moral,is an experienced entrepreneur and a founder of Reunion and served at Chief Executive Officer until September 2022. In 2014, he was the founder and CEO of CanvasRx Inc. and Canadian Cannabis Clinics, which grew to be the largest cannabis clinic company in Canada. In 2016, CanvasRx was acquired by Aurora Cannabis Inc. (NYSE: ACB) ("Aurora") and he joined Aurora's board of directors. During his time at Aurora, Mr. del Moral ensured that CanvasRx continued to grow and achieve its milestones as well as assisted in corporate development, M&A and strategy. After leaving Aurora in 2018, Mr. del Moral assumed the role of CEO of Trait Biosciences Inc., a leading biotech company in the hemp and cannabis industries. Prior to his time in the cannabis industry, Mr. del Moral co-founded Newten Home Comfort, a fast growing home services company acquired by Just Energy Inc. in 2009. Mr. del Moral was conferred a Bachelor of Commerce Degree (Finance and Entrepreneurship) from McGill University in June 2001. - Joseph del Moral是一位经验丰富的企业家，也是Reunion的创始人，曾担任首席执行官至2022年9月。2014年，他是CanvasRx Inc.和Canadian Cannabis Clinics的创始人和首席执行官，后者成长为加拿大最大的大麻诊所公司。2016年，CanvasRx被Aurora Cannabis Inc.（纽约证券交易所代码：ACB）（“Aurora”）收购，他加入了Aurora的董事会。在Aurora任职期间，del Moral先生确保CanvasRx继续发展并实现其里程碑，并协助公司发展、并购和战略。2018年离开Aurora后，德尔莫拉尔担任大麻和大麻行业领先的生物技术公司Trait Biosciences Inc.的首席执行官。在进入大麻行业之前，德尔莫拉尔与他人共同创立了Newten Home Comfort，这是一家快速发展的家庭服务公司，于2009年被Just Energy Inc.收购。2001年6月，del Moral先生被麦吉尔大学授予商业学士学位（金融和创业）。
- Joseph del Moral,is an experienced entrepreneur and a founder of Reunion and served at Chief Executive Officer until September 2022. In 2014, he was the founder and CEO of CanvasRx Inc. and Canadian Cannabis Clinics, which grew to be the largest cannabis clinic company in Canada. In 2016, CanvasRx was acquired by Aurora Cannabis Inc. (NYSE: ACB) ("Aurora") and he joined Aurora's board of directors. During his time at Aurora, Mr. del Moral ensured that CanvasRx continued to grow and achieve its milestones as well as assisted in corporate development, M&A and strategy. After leaving Aurora in 2018, Mr. del Moral assumed the role of CEO of Trait Biosciences Inc., a leading biotech company in the hemp and cannabis industries. Prior to his time in the cannabis industry, Mr. del Moral co-founded Newten Home Comfort, a fast growing home services company acquired by Just Energy Inc. in 2009. Mr. del Moral was conferred a Bachelor of Commerce Degree (Finance and Entrepreneurship) from McGill University in June 2001.
- Hannan Fleiman
-
汉南·弗莱曼是一名连续创业者，曾与他人共同创立和经营多家公司，包括他担任总裁至2022年8月的留尼旺、CanvasRx Inc.、Canadian Cannabis Clinic和Dominion Home Insulation。在创立这些公司之前，弗莱曼管理着梯瓦加拿大公司的医院部门、动物保健和非处方药部门。Fleiman先生是合同研究组织MedicNL的董事会成员，该组织被MGC制药有限公司（ASX：MXC）收购，他是Abacus Health的董事会成员，在成功出售给Charlotte's Web Holdings，Inc.（CSE：CWEB）之前，他领导审计和薪酬委员会。弗莱曼先生于2006年6月获得麦克马斯特大学的MBA学位，并于2003年6月获得圭尔夫大学的学士学位。
Hannan Fleiman,is a serial entrepreneur and has co-founded and operated several companies, including Reunion where he served as president until August 2022, CanvasRx Inc., Canadian Cannabis Clinic and Dominion Home Insulation. Prior to founding these companies, Mr. Fleiman managed the hospital department, animal health and OTC divisions at Teva Canada. Mr. Fleiman was a board member of MedicNL, a contract research organization, which was acquired by MGC pharmaceuticals Ltd. (ASX: MXC) and was a board member of Abacus Health, where he headed the audit and compensation committees before the successful sale to Charlotte's Web Holdings, Inc. (CSE: CWEB). Mr. Fleiman earned his MBA from McMaster University in June 2006 and his BSc from University of Guelph in June 2003. - 汉南·弗莱曼是一名连续创业者，曾与他人共同创立和经营多家公司，包括他担任总裁至2022年8月的留尼旺、CanvasRx Inc.、Canadian Cannabis Clinic和Dominion Home Insulation。在创立这些公司之前，弗莱曼管理着梯瓦加拿大公司的医院部门、动物保健和非处方药部门。Fleiman先生是合同研究组织MedicNL的董事会成员，该组织被MGC制药有限公司（ASX：MXC）收购，他是Abacus Health的董事会成员，在成功出售给Charlotte's Web Holdings，Inc.（CSE：CWEB）之前，他领导审计和薪酬委员会。弗莱曼先生于2006年6月获得麦克马斯特大学的MBA学位，并于2003年6月获得圭尔夫大学的学士学位。
- Hannan Fleiman,is a serial entrepreneur and has co-founded and operated several companies, including Reunion where he served as president until August 2022, CanvasRx Inc., Canadian Cannabis Clinic and Dominion Home Insulation. Prior to founding these companies, Mr. Fleiman managed the hospital department, animal health and OTC divisions at Teva Canada. Mr. Fleiman was a board member of MedicNL, a contract research organization, which was acquired by MGC pharmaceuticals Ltd. (ASX: MXC) and was a board member of Abacus Health, where he headed the audit and compensation committees before the successful sale to Charlotte's Web Holdings, Inc. (CSE: CWEB). Mr. Fleiman earned his MBA from McMaster University in June 2006 and his BSc from University of Guelph in June 2003.
- Helen Boudreau
-
Helen Boudreau是一位退休的高级管理人员，在生物技术、制药、咨询和银行业拥有30年的经验。2018年至2019年，她担任非盈利生物技术公司比尔和梅琳达·盖茨医学研究所的首席运营官。此前，她曾担任公共和私营生物技术公司、Proteostasis Therapeutics（2017-2018年）和FORMA Therapeutics（2014-2017年）的首席财务官。海伦曾在诺华（2008-2014年）和辉瑞（1999-2008年）担任战略和高级财务职务，包括全球首席财务官、肿瘤业务部门首席财务官、美国企业首席财务官、投资者关系副总裁、财务副总裁、客户业务部门和商业运营副总裁，以及财务副总裁全球研发。海伦的职业生涯始于美国银行（1987-1991年），曾在麦肯锡公司担任项目经理（1993-1996年），并在百胜集团担任战略规划总监。品牌/百事可乐（1996-1999年）。海伦目前是医疗保健改善公司Premier, Inc.（纳斯达克股票代码：PINC）、专注于肿瘤学和自身免疫性疾病的生物技术公司Shattuck实验室（纳斯达克股票代码：STTK）和专注于罕见病的生物技术公司Rallybio（纳斯达克股票代码：RLYB）的董事会成员。海伦1987年以优异成绩获得马里兰大学经济学学士学位，1993年获得弗吉尼亚大学达顿商学院MBA学位。
Helen Boudreau,is a retired senior executive with 30 years experience across biotech, pharmaceuticals, consulting, and banking industries. She was most recently COO of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech, from 2018 to 2019. Previously, she served as CFO for public and private biotechs, Proteostasis Therapeutics (2017-2018) and FORMA Therapeutics (2014-2017). Helen worked at Novartis (2008-2014) and Pfizer (1999-2008), serving in strategy and senior finance roles, including global CFO Oncology business unit, CFO US Corporate, VP Investor Relations, VP Finance, Customer Business Unit and Commercial Operations, and VP Finance Global R&D. Helen started her career in banking at Bank of America (1987-1991), was an engagement manager at McKinsey & Company (1993-1996), and a Director of Strategic Planning at YUM! Brands/PepsiCo (1996-1999). Helen is currently a member of the board of Premier, Inc. (NASDAQ: PINC), a healthcare improvement company, Shattuck Labs (NASDAQ:STTK), a biotech focused on oncology and autoimmune disease, and Rallybio, (NASDAQ:RLYB) a biotech company focused on rare diseases. Helen earned a BA in Economics, summa cum laude, from the University of Maryland in 1987, and an MBA from the Darden Graduate School of Business at the University of Virginia in 1993. - Helen Boudreau是一位退休的高级管理人员，在生物技术、制药、咨询和银行业拥有30年的经验。2018年至2019年，她担任非盈利生物技术公司比尔和梅琳达·盖茨医学研究所的首席运营官。此前，她曾担任公共和私营生物技术公司、Proteostasis Therapeutics（2017-2018年）和FORMA Therapeutics（2014-2017年）的首席财务官。海伦曾在诺华（2008-2014年）和辉瑞（1999-2008年）担任战略和高级财务职务，包括全球首席财务官、肿瘤业务部门首席财务官、美国企业首席财务官、投资者关系副总裁、财务副总裁、客户业务部门和商业运营副总裁，以及财务副总裁全球研发。海伦的职业生涯始于美国银行（1987-1991年），曾在麦肯锡公司担任项目经理（1993-1996年），并在百胜集团担任战略规划总监。品牌/百事可乐（1996-1999年）。海伦目前是医疗保健改善公司Premier, Inc.（纳斯达克股票代码：PINC）、专注于肿瘤学和自身免疫性疾病的生物技术公司Shattuck实验室（纳斯达克股票代码：STTK）和专注于罕见病的生物技术公司Rallybio（纳斯达克股票代码：RLYB）的董事会成员。海伦1987年以优异成绩获得马里兰大学经济学学士学位，1993年获得弗吉尼亚大学达顿商学院MBA学位。
- Helen Boudreau,is a retired senior executive with 30 years experience across biotech, pharmaceuticals, consulting, and banking industries. She was most recently COO of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech, from 2018 to 2019. Previously, she served as CFO for public and private biotechs, Proteostasis Therapeutics (2017-2018) and FORMA Therapeutics (2014-2017). Helen worked at Novartis (2008-2014) and Pfizer (1999-2008), serving in strategy and senior finance roles, including global CFO Oncology business unit, CFO US Corporate, VP Investor Relations, VP Finance, Customer Business Unit and Commercial Operations, and VP Finance Global R&D. Helen started her career in banking at Bank of America (1987-1991), was an engagement manager at McKinsey & Company (1993-1996), and a Director of Strategic Planning at YUM! Brands/PepsiCo (1996-1999). Helen is currently a member of the board of Premier, Inc. (NASDAQ: PINC), a healthcare improvement company, Shattuck Labs (NASDAQ:STTK), a biotech focused on oncology and autoimmune disease, and Rallybio, (NASDAQ:RLYB) a biotech company focused on rare diseases. Helen earned a BA in Economics, summa cum laude, from the University of Maryland in 1987, and an MBA from the Darden Graduate School of Business at the University of Virginia in 1993.
- Dieter Weinand
-
Dieter Weinand是一位经验丰富的高管，在制药和生物技术行业拥有30多年的经验。魏南德先生目前担任Replimune Group公司（纳斯达克股票代码：REPL）董事会主席。此前，韦南先生曾担任初级保健执行副总裁，并于2018年11月至2020年2月担任赛诺菲执行委员会成员。在加入赛诺菲之前，魏南德先生是拜耳制药公司的首席执行官兼管理委员会主席，拜耳公司的管理委员会成员。在加入赛诺菲和拜耳之前，韦南德先生曾在制药行业的商业、运营和战略领域担任过各种职务。其中包括辉瑞、百时美施贵宝和大冢等公司在不同治疗领域和地区的职责。魏南德先生在纽约长岛大学获得药理学和毒理学硕士学位，在纽约康考迪亚学院获得生物学学士学位。魏南德先生曾是美国药品研究和制造商协会（PhRMA）、欧洲药品工业和协会联合会（EFPIA）和国际药品制造商联合会（IFPMA）的董事会成员，并曾担任HealthPrize Technologies的董事会成员。
Dieter Weinand,is an experienced executive with over 30 years of experience in the pharmaceuticals and biotech industries. Mr. Weinand presently serves as the chairman of the board of directors of Replimune Group Inc. (NASDAQ: REPL). Previously, Mr. Weinand served as the Executive Vice President of Primary Care and was a member of the Executive Committee at Sanofi from November 2018 to February 2020. Before moving to Sanofi, Mr. Weinand was CEO and Chairman of the Board of Management of Bayer Pharma AG and member of the Management Board at Bayer AG. Prior to his work at Sanofi and Bayer, Mr. Weinand has held various positions in commercial, operational, and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer, Bristol Myers Squibb, and Otsuka. Mr. Weinand earned an MS in Pharmacology and Toxicology from Long Island University, New York, and a BA in Biology from Concordia College, New York. Mr. Weinand is a former board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries & Associations (EFPIA), and the International Federation of Pharmaceutical Manufacturers (IFPMA) and served as a member of the Board of Directors of HealthPrize Technologies. - Dieter Weinand是一位经验丰富的高管，在制药和生物技术行业拥有30多年的经验。魏南德先生目前担任Replimune Group公司（纳斯达克股票代码：REPL）董事会主席。此前，韦南先生曾担任初级保健执行副总裁，并于2018年11月至2020年2月担任赛诺菲执行委员会成员。在加入赛诺菲之前，魏南德先生是拜耳制药公司的首席执行官兼管理委员会主席，拜耳公司的管理委员会成员。在加入赛诺菲和拜耳之前，韦南德先生曾在制药行业的商业、运营和战略领域担任过各种职务。其中包括辉瑞、百时美施贵宝和大冢等公司在不同治疗领域和地区的职责。魏南德先生在纽约长岛大学获得药理学和毒理学硕士学位，在纽约康考迪亚学院获得生物学学士学位。魏南德先生曾是美国药品研究和制造商协会（PhRMA）、欧洲药品工业和协会联合会（EFPIA）和国际药品制造商联合会（IFPMA）的董事会成员，并曾担任HealthPrize Technologies的董事会成员。
- Dieter Weinand,is an experienced executive with over 30 years of experience in the pharmaceuticals and biotech industries. Mr. Weinand presently serves as the chairman of the board of directors of Replimune Group Inc. (NASDAQ: REPL). Previously, Mr. Weinand served as the Executive Vice President of Primary Care and was a member of the Executive Committee at Sanofi from November 2018 to February 2020. Before moving to Sanofi, Mr. Weinand was CEO and Chairman of the Board of Management of Bayer Pharma AG and member of the Management Board at Bayer AG. Prior to his work at Sanofi and Bayer, Mr. Weinand has held various positions in commercial, operational, and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer, Bristol Myers Squibb, and Otsuka. Mr. Weinand earned an MS in Pharmacology and Toxicology from Long Island University, New York, and a BA in Biology from Concordia College, New York. Mr. Weinand is a former board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries & Associations (EFPIA), and the International Federation of Pharmaceutical Manufacturers (IFPMA) and served as a member of the Board of Directors of HealthPrize Technologies.
- Fred Grossman
-
Fred Grossman是一位经验丰富的高管，在制药和生物技术行业拥有超过25年的经验。在加入留尼旺之前，格罗斯曼博士曾任Empyrean Neuroscience首席医疗官兼转化医学主管（2022-2023年）、Mesoblast Ltd.首席医疗官（2019-2022年）和Glenmark Pharmaceuticals总裁兼首席医疗官（2018-2019年）。他曾在大型制药公司担任行政领导职务，包括礼来、强生、百时美施贵宝和Sunovion。他负责领导开发、批准和支持推出众多全球药物，以满足治疗领域（尤其是中枢神经系统）的重大未满足医疗需求。他担任过学术职务，并撰写过许多科学出版物。他在费城的哈内曼大学和马里兰州贝塞斯达的国家心理健康研究所接受了精神病学培训，并在国家卫生研究院临床药理科完成了研究金。格罗斯曼博士是一位获得委员会认证的精神病学家和美国精神病学协会会员。
Fred Grossman,is an experienced executive with over 25 years of experience in the pharmaceuticals and biotech industries. Before joining Reunion, Dr. Grossman was Chief Medical Officer and Head of Translational Medicine at Empyrean Neuroscience (2022-2023), Chief Medical Officer of Mesoblast Ltd. (2019-2022) and President and Chief Medical Officer of Glenmark Pharmaceuticals (2018-2019). He has held executive leadership positions in large pharmaceutical companies, including Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He has been responsible for leading the development, approval, and supporting the launch of numerous global medications addressing significant unmet medical needs across therapeutic areas, particularly in the CNS. He has held academic appointments and has authored numerous scientific publications. He was trained in psychiatry at Hahnemann University in Philadelphia and at the National Institute of Mental Health in Bethesda, Maryland and completed a Fellowship in the Section on Clinical Pharmacology at the National Institutes of Health. Dr. Grossman is a board-certified psychiatrist and Fellow of the American Psychiatric Association. - Fred Grossman是一位经验丰富的高管，在制药和生物技术行业拥有超过25年的经验。在加入留尼旺之前，格罗斯曼博士曾任Empyrean Neuroscience首席医疗官兼转化医学主管（2022-2023年）、Mesoblast Ltd.首席医疗官（2019-2022年）和Glenmark Pharmaceuticals总裁兼首席医疗官（2018-2019年）。他曾在大型制药公司担任行政领导职务，包括礼来、强生、百时美施贵宝和Sunovion。他负责领导开发、批准和支持推出众多全球药物，以满足治疗领域（尤其是中枢神经系统）的重大未满足医疗需求。他担任过学术职务，并撰写过许多科学出版物。他在费城的哈内曼大学和马里兰州贝塞斯达的国家心理健康研究所接受了精神病学培训，并在国家卫生研究院临床药理科完成了研究金。格罗斯曼博士是一位获得委员会认证的精神病学家和美国精神病学协会会员。
- Fred Grossman,is an experienced executive with over 25 years of experience in the pharmaceuticals and biotech industries. Before joining Reunion, Dr. Grossman was Chief Medical Officer and Head of Translational Medicine at Empyrean Neuroscience (2022-2023), Chief Medical Officer of Mesoblast Ltd. (2019-2022) and President and Chief Medical Officer of Glenmark Pharmaceuticals (2018-2019). He has held executive leadership positions in large pharmaceutical companies, including Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He has been responsible for leading the development, approval, and supporting the launch of numerous global medications addressing significant unmet medical needs across therapeutic areas, particularly in the CNS. He has held academic appointments and has authored numerous scientific publications. He was trained in psychiatry at Hahnemann University in Philadelphia and at the National Institute of Mental Health in Bethesda, Maryland and completed a Fellowship in the Section on Clinical Pharmacology at the National Institutes of Health. Dr. Grossman is a board-certified psychiatrist and Fellow of the American Psychiatric Association.
- Greg Mayes
-
Greg Mayes，拥有20多年的药物开发经验，最近担任Antios Therapeutics总裁兼首席执行官（2020-2022年）。在加入Antios之前，Greg创立了Engage Therapeutics，并担任公司总裁兼首席执行官（2017-2020年）。格雷格带领Engage完成了成功的2b期疗效研究，这是第一个也是唯一一个快速终止活动性癫痫发作的药物-器械组合，这导致该公司被UCB收购。他还在Advaxis免疫疗法公司担任首席运营官，在ImClone系统公司担任副总裁、总法律顾问和首席合规官，在领导筹资、合作和收购方面发挥了不可或缺的作用。
Greg Mayes,has over 20 years of pharmaceutical drug development experience, most recently as President and CEO of Antios Therapeutics (2020-2022). Prior to Antios, Greg founded Engage Therapeutics and served as the company's President and CEO (2017-2020). Greg led Engage through successful Phase 2b efficacy studies of the first and only drug-device combination for rapid termination of an active epileptic seizure, which led to the company's acquisition by UCB. He also played integral roles in leading fund-raising, partnering, and acquisitions at Advaxis Immunotherapies as COO and at ImClone Systems Corporation, as Vice President, General Counsel, and Chief Compliance Officer. - Greg Mayes，拥有20多年的药物开发经验，最近担任Antios Therapeutics总裁兼首席执行官（2020-2022年）。在加入Antios之前，Greg创立了Engage Therapeutics，并担任公司总裁兼首席执行官（2017-2020年）。格雷格带领Engage完成了成功的2b期疗效研究，这是第一个也是唯一一个快速终止活动性癫痫发作的药物-器械组合，这导致该公司被UCB收购。他还在Advaxis免疫疗法公司担任首席运营官，在ImClone系统公司担任副总裁、总法律顾问和首席合规官，在领导筹资、合作和收购方面发挥了不可或缺的作用。
- Greg Mayes,has over 20 years of pharmaceutical drug development experience, most recently as President and CEO of Antios Therapeutics (2020-2022). Prior to Antios, Greg founded Engage Therapeutics and served as the company's President and CEO (2017-2020). Greg led Engage through successful Phase 2b efficacy studies of the first and only drug-device combination for rapid termination of an active epileptic seizure, which led to the company's acquisition by UCB. He also played integral roles in leading fund-raising, partnering, and acquisitions at Advaxis Immunotherapies as COO and at ImClone Systems Corporation, as Vice President, General Counsel, and Chief Compliance Officer.
高管简历
中英对照 | 中文 | 英文- Edward Smith
Edward Smith自2020年4月起担任董事。史密斯先生目前担任MarinusPharmaceuticals，Inc.的首席财务官。纳斯达克股票代码:MRNS，一家临床阶段的制药公司，专注于开发和商业化创新疗法，以治疗患有罕见癫痫疾病的患者。2013年在Marinus Pharmaceuticals任职之前，Smith先生担任PolyMedix，Inc.的首席财务官，在PolyMedix，Inc.任职之前，他担任Inkine Pharmaceutical Company，Inc.的财务执行董事。
Edward Smith has been a director since April 2020. Edward served as the Chief Financial Officer of LAVA Therapeutics N.V. Nasdaq: LVTX, a clinical stage pharmaceutical company focused on developing novel immuno-oncology therapeutics. Prior to that, he served as Chief Financial Officer of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders, and PolyMedix, Inc., a clinical stage pharmaceutical company focused on developing a novel class of antibiotics for the treatment of infectious diseases. Before his time at PolyMedix, Inc. he served as the executive director of finance at InKine Pharmaceutical Company, Inc. and held various positions in public accounting, most recently in the audit practice of Deloitte.- Edward Smith自2020年4月起担任董事。史密斯先生目前担任MarinusPharmaceuticals，Inc.的首席财务官。纳斯达克股票代码:MRNS，一家临床阶段的制药公司，专注于开发和商业化创新疗法，以治疗患有罕见癫痫疾病的患者。2013年在Marinus Pharmaceuticals任职之前，Smith先生担任PolyMedix，Inc.的首席财务官，在PolyMedix，Inc.任职之前，他担任Inkine Pharmaceutical Company，Inc.的财务执行董事。
- Edward Smith has been a director since April 2020. Edward served as the Chief Financial Officer of LAVA Therapeutics N.V. Nasdaq: LVTX, a clinical stage pharmaceutical company focused on developing novel immuno-oncology therapeutics. Prior to that, he served as Chief Financial Officer of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders, and PolyMedix, Inc., a clinical stage pharmaceutical company focused on developing a novel class of antibiotics for the treatment of infectious diseases. Before his time at PolyMedix, Inc. he served as the executive director of finance at InKine Pharmaceutical Company, Inc. and held various positions in public accounting, most recently in the audit practice of Deloitte.
- Greg Mayes
Greg Mayes，拥有20多年的药物开发经验，最近担任Antios Therapeutics总裁兼首席执行官（2020-2022年）。在加入Antios之前，Greg创立了Engage Therapeutics，并担任公司总裁兼首席执行官（2017-2020年）。格雷格带领Engage完成了成功的2b期疗效研究，这是第一个也是唯一一个快速终止活动性癫痫发作的药物-器械组合，这导致该公司被UCB收购。他还在Advaxis免疫疗法公司担任首席运营官，在ImClone系统公司担任副总裁、总法律顾问和首席合规官，在领导筹资、合作和收购方面发挥了不可或缺的作用。
Greg Mayes,has over 20 years of pharmaceutical drug development experience, most recently as President and CEO of Antios Therapeutics (2020-2022). Prior to Antios, Greg founded Engage Therapeutics and served as the company's President and CEO (2017-2020). Greg led Engage through successful Phase 2b efficacy studies of the first and only drug-device combination for rapid termination of an active epileptic seizure, which led to the company's acquisition by UCB. He also played integral roles in leading fund-raising, partnering, and acquisitions at Advaxis Immunotherapies as COO and at ImClone Systems Corporation, as Vice President, General Counsel, and Chief Compliance Officer.- Greg Mayes，拥有20多年的药物开发经验，最近担任Antios Therapeutics总裁兼首席执行官（2020-2022年）。在加入Antios之前，Greg创立了Engage Therapeutics，并担任公司总裁兼首席执行官（2017-2020年）。格雷格带领Engage完成了成功的2b期疗效研究，这是第一个也是唯一一个快速终止活动性癫痫发作的药物-器械组合，这导致该公司被UCB收购。他还在Advaxis免疫疗法公司担任首席运营官，在ImClone系统公司担任副总裁、总法律顾问和首席合规官，在领导筹资、合作和收购方面发挥了不可或缺的作用。
- Greg Mayes,has over 20 years of pharmaceutical drug development experience, most recently as President and CEO of Antios Therapeutics (2020-2022). Prior to Antios, Greg founded Engage Therapeutics and served as the company's President and CEO (2017-2020). Greg led Engage through successful Phase 2b efficacy studies of the first and only drug-device combination for rapid termination of an active epileptic seizure, which led to the company's acquisition by UCB. He also played integral roles in leading fund-raising, partnering, and acquisitions at Advaxis Immunotherapies as COO and at ImClone Systems Corporation, as Vice President, General Counsel, and Chief Compliance Officer.
- Robert Alexander
Robert Alexander,2023年1月加入留尼汪岛，担任首席医疗官。除在留尼旺任职外，他还担任邦纳阿尔茨海默氏病研究所阿尔茨海默氏病预防计划首席科学官（2021年至今）和亚利桑那大学凤凰城医学院精神病学系研究教授（2021年至今）。此前，他曾担任武田神经科学治疗部门副总裁（2017-2020年）、辉瑞神经科学和疼痛部门副总裁兼临床主管（2015-2017年）、阿斯利康中枢神经系统和疼痛创新药物部门（iMed）临床副总裁（2012-2015年），以及GSK和默沙东发现医学和神经科学部门的其他职位。亚历山大博士在芝加哥大学普利兹克医学院获得医学博士学位。他获得了美国精神病学和神经病学委员会的认证，专攻精神药理学，在广泛的神经和精神病学适应症方面进行过或指导过临床研究。
Robert Alexander,Joined Reunion as Chief Medical Officer in January of 2023. He is, in addition to his role at Reunion, currently the Chief Scientific Officer of the Alzheimer's Prevention Initiative at the Banner Alzheimer's Institute (2021-present) and a Research Professor in the Department of Psychiatry at the University of Arizona School of Medicine – Phoenix (2021-present). Previously, he held positions as VP in the neuroscience therapeutic area unit at Takeda (2017-2020), VP and head of clinical for the neuroscience and pain at Pfizer (2015-2017), VP of clinical for CNS and the pain innovative medicines unit (iMed) at AstraZeneca (2012-2015), as well as other positions in discovery medicine and neuroscience at GSK and Merck. Dr. Alexander received his M.D. degree from The University of Chicago Pritzker School of Medicine. He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology, having conducted or supervised clinical studies in a broad range of neurologic and psychiatric indications.- Robert Alexander,2023年1月加入留尼汪岛，担任首席医疗官。除在留尼旺任职外，他还担任邦纳阿尔茨海默氏病研究所阿尔茨海默氏病预防计划首席科学官（2021年至今）和亚利桑那大学凤凰城医学院精神病学系研究教授（2021年至今）。此前，他曾担任武田神经科学治疗部门副总裁（2017-2020年）、辉瑞神经科学和疼痛部门副总裁兼临床主管（2015-2017年）、阿斯利康中枢神经系统和疼痛创新药物部门（iMed）临床副总裁（2012-2015年），以及GSK和默沙东发现医学和神经科学部门的其他职位。亚历山大博士在芝加哥大学普利兹克医学院获得医学博士学位。他获得了美国精神病学和神经病学委员会的认证，专攻精神药理学，在广泛的神经和精神病学适应症方面进行过或指导过临床研究。
- Robert Alexander,Joined Reunion as Chief Medical Officer in January of 2023. He is, in addition to his role at Reunion, currently the Chief Scientific Officer of the Alzheimer's Prevention Initiative at the Banner Alzheimer's Institute (2021-present) and a Research Professor in the Department of Psychiatry at the University of Arizona School of Medicine – Phoenix (2021-present). Previously, he held positions as VP in the neuroscience therapeutic area unit at Takeda (2017-2020), VP and head of clinical for the neuroscience and pain at Pfizer (2015-2017), VP of clinical for CNS and the pain innovative medicines unit (iMed) at AstraZeneca (2012-2015), as well as other positions in discovery medicine and neuroscience at GSK and Merck. Dr. Alexander received his M.D. degree from The University of Chicago Pritzker School of Medicine. He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology, having conducted or supervised clinical studies in a broad range of neurologic and psychiatric indications.
- Nathan Bryson
Nathan Bryson，拥有30年的药物开发经验。在获得放射性药物化学博士学位（1988年，麻省理工学院）以及在路易巴斯德大学（法国斯特拉斯堡）和麻省理工学院从事催化和聚合物博士后研究后，布赖森博士于1990年作为创始科学家加入Flamel Technologies（现为Avadel Pharma），最终在研发、工艺开发和商业化方面建立并领导团队。在不断扩大职位后，布赖森博士在Bionisis（FR）和Matregen（加拿大）担任研发副总裁，2005年转到Cynapsus（前身为Cannasat）的CSO职位，2014年转到Acerus Pharmaceuticals Corporation。在Cynapsus，他负责Kinmobil（现已在加拿大和美国获得批准）的化学制造控制和早期开发，而在Acerus，他负责研究、临床开发、医疗和监管事务以及生产。在获得博士学位之前，内森获得了理学学士学位。（化学），1984年授予，奥本大学。
Nathan Bryson,has 30 years of experience in pharmaceutical drug development. After receiving his Ph.D. in radiopharmaceutical chemistry (MIT, 1988) and successive post-doctoral studies in catalysis and polymers at the University Louis Pasteur (Strasbourg, France) and MIT, Dr. Bryson joined Flamel Technologies (now Avadel Pharma) as a founding scientist in 1990, eventually developing and leading teams in R&D, process development and commercialization. After expanding roles, as Vice President R&D at Bionisis (FR) and Matregen (Canada), Dr. Bryson transitioned to CSO roles at Cynapsus in 2005 (formerly, Cannasat) and to Acerus Pharmaceuticals Corporation in 2014. At Cynapsus, he led Chemistry-Manufacturing-Controls and early-stage development of Kinmobil (now approved in Canada and US), while at Acerus, he headed research, clinical development, medical and regulatory affairs, as well as production. Prior to his doctorate, Nathan received a B.Sc. (chemistry), conferred in 1984, from Auburn University.- Nathan Bryson，拥有30年的药物开发经验。在获得放射性药物化学博士学位（1988年，麻省理工学院）以及在路易巴斯德大学（法国斯特拉斯堡）和麻省理工学院从事催化和聚合物博士后研究后，布赖森博士于1990年作为创始科学家加入Flamel Technologies（现为Avadel Pharma），最终在研发、工艺开发和商业化方面建立并领导团队。在不断扩大职位后，布赖森博士在Bionisis（FR）和Matregen（加拿大）担任研发副总裁，2005年转到Cynapsus（前身为Cannasat）的CSO职位，2014年转到Acerus Pharmaceuticals Corporation。在Cynapsus，他负责Kinmobil（现已在加拿大和美国获得批准）的化学制造控制和早期开发，而在Acerus，他负责研究、临床开发、医疗和监管事务以及生产。在获得博士学位之前，内森获得了理学学士学位。（化学），1984年授予，奥本大学。
- Nathan Bryson,has 30 years of experience in pharmaceutical drug development. After receiving his Ph.D. in radiopharmaceutical chemistry (MIT, 1988) and successive post-doctoral studies in catalysis and polymers at the University Louis Pasteur (Strasbourg, France) and MIT, Dr. Bryson joined Flamel Technologies (now Avadel Pharma) as a founding scientist in 1990, eventually developing and leading teams in R&D, process development and commercialization. After expanding roles, as Vice President R&D at Bionisis (FR) and Matregen (Canada), Dr. Bryson transitioned to CSO roles at Cynapsus in 2005 (formerly, Cannasat) and to Acerus Pharmaceuticals Corporation in 2014. At Cynapsus, he led Chemistry-Manufacturing-Controls and early-stage development of Kinmobil (now approved in Canada and US), while at Acerus, he headed research, clinical development, medical and regulatory affairs, as well as production. Prior to his doctorate, Nathan received a B.Sc. (chemistry), conferred in 1984, from Auburn University.
- Curtis Weber
柯蒂斯韦伯拥有超过10年的公司律师经验，在生命科学行业拥有专业知识，为上市公司和私营公司提供咨询服务。Weber先生曾在Dechert LLP（2018-2021年）和Cravath，Swaine & Moore LLP（2011-2014年）担任公司助理，并在Gemini Space Station LLC（2021-2022年）和FS Investments（2014-2018年）担任高级公司法律顾问。Weber先生毕业于密苏里大学（学士和硕士）和宾夕法尼亚大学法学院（法学博士）
Curtis Weber,has over 10 years of experience as a corporate attorney, with expertise in the life sciences industry advising public and private companies. Mr. Weber previously worked as a corporate associate at Dechert LLP (2018-2021) and Cravath, Swaine & Moore LLP (2011-2014), and as senior corporate counsel at Gemini Space Station LLC (2021-2022) and FS Investments (2014-2018). Mr. Weber is a graduate of the University of Missouri (B.A. and M.Acc.) and the University of Pennsylvania Law School (J.D.)- 柯蒂斯韦伯拥有超过10年的公司律师经验，在生命科学行业拥有专业知识，为上市公司和私营公司提供咨询服务。Weber先生曾在Dechert LLP（2018-2021年）和Cravath，Swaine & Moore LLP（2011-2014年）担任公司助理，并在Gemini Space Station LLC（2021-2022年）和FS Investments（2014-2018年）担任高级公司法律顾问。Weber先生毕业于密苏里大学（学士和硕士）和宾夕法尼亚大学法学院（法学博士）
- Curtis Weber,has over 10 years of experience as a corporate attorney, with expertise in the life sciences industry advising public and private companies. Mr. Weber previously worked as a corporate associate at Dechert LLP (2018-2021) and Cravath, Swaine & Moore LLP (2011-2014), and as senior corporate counsel at Gemini Space Station LLC (2021-2022) and FS Investments (2014-2018). Mr. Weber is a graduate of the University of Missouri (B.A. and M.Acc.) and the University of Pennsylvania Law School (J.D.)